PURPOSE:Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease. PATIENTS AND METHODS: Our study population included 3,799 women randomly assigned to five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative disease (ie, B-13, B-14, B-19, B-20, and B-23) who underwentlumpectomy and whole breast irradiation with or without adjuvant systemic therapy. Cumulative incidences of ipsilateral breast tumor recurrence (IBTR) and other locoregional recurrence (oLRR) were calculated, along with distant-disease-free interval (DDFI) and overall survival (OS) after these events. Cox models were employed to model mortality by using clinical and pathologic factors jointly with these events. RESULTS:Four hundred nineteen patients (11.0%) experiencedLRF: 342 (9.0%) experienced IBTR, and 77 (2.0%) experienced oLRR. The 12-year cumulative incidences of IBTR and oLRR in patients treated with adjuvant systemic therapy were 6.6% and 1.8%, respectively. Overall, 37.1% of IBTRs and 72.7% of oLRRs occurred within 5 years of diagnosis. Older age, black race, higher body mass index (BMI), larger tumors, and occurrence of IBTR or oLRR were significantly associated with increased mortality. The 5-year OS after IBTR and oLRR were 76.6% and 34.9%, respectively. Adjusted hazard ratios for mortality associated with IBTR and oLRR were significantly higher in estrogen receptor (ER)-negative patients than in ER-positive patients (P = .002 and P < .0001, respectively). Patients with early LRF had worse OS and DDFI than those with later-occurring LRF. CONCLUSION: Although LRF is uncommon in patients with node-negative breast cancer who are treated with lumpectomy, radiation, and adjuvant systemic therapy, those who do develop LRF have substantially worse OS and DDFI.
RCT Entities:
PURPOSE: Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease. PATIENTS AND METHODS: Our study population included 3,799 women randomly assigned to five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative disease (ie, B-13, B-14, B-19, B-20, and B-23) who underwent lumpectomy and whole breast irradiation with or without adjuvant systemic therapy. Cumulative incidences of ipsilateral breast tumor recurrence (IBTR) and other locoregional recurrence (oLRR) were calculated, along with distant-disease-free interval (DDFI) and overall survival (OS) after these events. Cox models were employed to model mortality by using clinical and pathologic factors jointly with these events. RESULTS: Four hundred nineteen patients (11.0%) experienced LRF: 342 (9.0%) experienced IBTR, and 77 (2.0%) experienced oLRR. The 12-year cumulative incidences of IBTR and oLRR in patients treated with adjuvant systemic therapy were 6.6% and 1.8%, respectively. Overall, 37.1% of IBTRs and 72.7% of oLRRs occurred within 5 years of diagnosis. Older age, black race, higher body mass index (BMI), larger tumors, and occurrence of IBTR or oLRR were significantly associated with increased mortality. The 5-year OS after IBTR and oLRR were 76.6% and 34.9%, respectively. Adjusted hazard ratios for mortality associated with IBTR and oLRR were significantly higher in estrogen receptor (ER)-negative patients than in ER-positive patients (P = .002 and P < .0001, respectively). Patients with early LRF had worse OS and DDFI than those with later-occurring LRF. CONCLUSION: Although LRF is uncommon in patients with node-negative breast cancer who are treated with lumpectomy, radiation, and adjuvant systemic therapy, those who do develop LRF have substantially worse OS and DDFI.
Authors: Eugene Huang; Thomas A Buchholz; Funda Meric; Savitri Krishnamurthy; Nadeem Q Mirza; Frederick C Ames; Barry W Feig; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Marsha D McNeese; Eric A Strom; Kelly K Hunt Journal: Cancer Date: 2002-11-15 Impact factor: 6.860
Authors: James J Dignam; Kelly Wieand; Karen A Johnson; Peter Raich; Stewart J Anderson; Carol Somkin; D Lawrence Wickerham Journal: Breast Cancer Res Treat Date: 2005-12-06 Impact factor: 4.872
Authors: B Fisher; S Anderson; E Tan-Chiu; N Wolmark; D L Wickerham; E R Fisher; N V Dimitrov; J N Atkins; N Abramson; S Merajver; E H Romond; C G Kardinal; H R Shibata; R G Margolese; W B Farrar Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: P H Elkhuizen; H J van Slooten; P C Clahsen; J Hermans; C J van de Velde; L C van den Broek; M J van de Vijver Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: James J Dignam; Kelly Wieand; Karen A Johnson; Bernard Fisher; Lei Xu; Eleftherios P Mamounas Journal: J Natl Cancer Inst Date: 2003-10-01 Impact factor: 13.506
Authors: Bernard Fisher; Jong-Hyeon Jeong; John Bryant; Stewart Anderson; James Dignam; Edwin R Fisher; Norman Wolmark Journal: Lancet Date: 2004 Sep 4-10 Impact factor: 79.321
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Paul Fishman; Debra P Ritzwoller Journal: Cancer Epidemiol Date: 2017-07-12 Impact factor: 2.984
Authors: Janie M Lee; Diana S M Buist; Nehmat Houssami; Emily C Dowling; Elkan F Halpern; G Scott Gazelle; Constance D Lehman; Louise M Henderson; Rebecca A Hubbard Journal: J Natl Cancer Inst Date: 2015-04-22 Impact factor: 13.506
Authors: Marieke E M van der Noordaa; Ileana Ioan; Emiel J Rutgers; Erik van Werkhoven; Claudette E Loo; Rosie Voorthuis; Jelle Wesseling; Japke van Urk; Terry Wiersma; Vincent Dezentje; Marie-Jeanne T F D Vrancken Peeters; Frederieke H van Duijnhoven Journal: Ann Surg Oncol Date: 2021-05-12 Impact factor: 5.344
Authors: Meena S Moran; Stuart J Schnitt; Armando E Giuliano; Jay R Harris; Seema A Khan; Janet Horton; Suzanne Klimberg; Mariana Chavez-MacGregor; Gary Freedman; Nehmat Houssami; Peggy L Johnson; Monica Morrow Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-01 Impact factor: 7.038
Authors: Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Miguel Martín; Johan W R Nortier; Alexander H G Paterson; Mothaffar F Rimawi; José Manuel Baena Cañada; Beat Thürlimann; Elizabeth Murray; Eleftherios P Mamounas; Charles E Geyer; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Norman Wolmark; Irene L Wapnir Journal: Lancet Oncol Date: 2014-01-16 Impact factor: 41.316
Authors: Irene L Wapnir; Shari Gelber; Stewart J Anderson; Eleftherios P Mamounas; André Robidoux; Miguel Martín; Johan W R Nortier; Charles E Geyer; Alexander H G Paterson; István Láng; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Meredith M Regan; Norman Wolmark; Stefan Aebi Journal: Ann Surg Oncol Date: 2016-09-23 Impact factor: 5.344